nerd
Senior Member
- Messages
- 863
Its not believed that dopaminergic drugs exacerbate cognitive decline, the theory is that the disease progresses causing more brain damage.
As the dopamine sensitive neurons that are involved with motor control die off the Levodopa causes more dopamine in dopamine sensitive neurons that are not dead but affect behaviour. Hence in advanced patients Levodopa loses motor control symptom control over time and Levodopa needs to be tapered down.
Two separate issues.
This has nothing to do with what I wrote. Two separate issues indeed. I think we have some kind of misunderstanding here.
The neurologist i see tries to avoid amantadine, it works ok in some patients but he finds its a messy drug and causes cognitive issues long term.
Amantadine is a dopaminergic drug. I provided some theories for why this cognitive decline your neurologist describes can happen. There are two working theories why Amantadine works against LID. First, because of its dopamine reuptake inhibition. Second, because of its NMDA antagonism. I've read papers arguing for both of these two theories. I consider the level of receptor activity that causes dyskinesia excitotoxic, which means that neural damage happens. Not necessarily in a clinical fashion, but chronically so that it can gradually contribute to cognitive decline.
Certainly, this isn't the only pathology that happens in Parkinson's and it doesn't have to be. Nothing excludes each other here.